Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Publication
, Journal Article
Mistry, PK; Balwani, M; Baris, HN; Turkia, HB; Burrow, TA; Charrow, J; Cox, GF; Danda, S; Dragosky, M; Drelichman, G; El-Beshlawy, A; Fraga, C ...
Published in: Blood Cells Mol Dis
July 2018
Duke Scholars
Published In
Blood Cells Mol Dis
DOI
EISSN
1096-0961
Publication Date
July 2018
Volume
71
Start / End Page
71 / 74
Location
United States
Related Subject Headings
- Pyrrolidines
- Immunology
- Humans
- Gaucher Disease
- Enzyme Replacement Therapy
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Mistry, P. K., Balwani, M., Baris, H. N., Turkia, H. B., Burrow, T. A., Charrow, J., … Cox, T. M. (2018). Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis, 71, 71–74. https://doi.org/10.1016/j.bcmd.2018.04.001
Mistry, Pramod K., Manisha Balwani, Hagit N. Baris, Hadhami Ben Turkia, T Andrew Burrow, Joel Charrow, Gerald F. Cox, et al. “Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.” Blood Cells Mol Dis 71 (July 2018): 71–74. https://doi.org/10.1016/j.bcmd.2018.04.001.
Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, et al. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2018 Jul;71:71–4.
Mistry, Pramod K., et al. “Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.” Blood Cells Mol Dis, vol. 71, July 2018, pp. 71–74. Pubmed, doi:10.1016/j.bcmd.2018.04.001.
Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM. Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1. Blood Cells Mol Dis. 2018 Jul;71:71–74.
Published In
Blood Cells Mol Dis
DOI
EISSN
1096-0961
Publication Date
July 2018
Volume
71
Start / End Page
71 / 74
Location
United States
Related Subject Headings
- Pyrrolidines
- Immunology
- Humans
- Gaucher Disease
- Enzyme Replacement Therapy
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences